Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107230 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL87921 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL22216666 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL60131 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL1828721 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL728754 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL24782761 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21422636 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21057384 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21057351 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822012-B2 | Molecular sieve Al-SSZ-63 composition of matter and synthesis thereof | CHEVRON U.S.A. INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822012-B2 | Molecular sieve Al-SSZ-63 composition of matter and synthesis thereof | CHEVRON U.S.A. INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170291822-A1 | MOLECULAR SIEVE AL-SSZ-63 COMPOSITION OF MATTER AND SYNTHESIS THEREOF | CHEVRON U.S.A. INC. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170291822-A1 | MOLECULAR SIEVE AL-SSZ-63 COMPOSITION OF MATTER AND SYNTHESIS THEREOF | CHEVRON U.S.A. INC. (US) | 2017-10-12 | — | — | US | disclosed |
| EP-1583717-A4 | MOLECULAR SIEVE SSZ-63 | CHEVRON USA INC (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1583717-A2 | MOLECULAR SIEVE SSZ-63 | Chevron U.S.A. Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6827843-B2 | N-cyclodecyl-N-methyl-pyrrolidinium cation as a structure-directing agent | CHEVRON U.S.A., INC. | 2004-12-07 | — | — | US | disclosed |
| US-6776973-B2 | PREPARED USING N-CYCLODECYL-N-METHYL-PYRROLIDINIUM CATION AS A STRUCTURE-DIRECTING AGENT, | CHEVRON U.S.A. INC. | 2004-08-17 | — | — | US | disclosed |
| WO-2004060794-A2 | MOLECULAR SIEVE SSZ-63 | CHEVRON U.S.A. INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040124123-A1 | Hydrocarbon conversion using molecular sieve SSZ-63 | CHEVRON U.S.A. INC. | 2004-07-01 | — | — | US | disclosed |
| US-20040127346-A1 | USING MOLECULAR SIEVE SSZ-63 FOR REDUCTION OF OXIDES OF NITROGEN IN A GAS STREAM | CHEVRON U.S.A. INC. | 2004-07-01 | — | — | US | disclosed |
| US-6733742-B1 | N-CYCLODECYL-N-METHYL-PYRROLIDINIUM CATION AS A STRUCTURE DIRECTING AGENT; SILICON OXIDE AND/OR GERMANIUM OXIDE WITH OXIDES OF ALUMINUN, GALLIUM, IRON, BORON, TITANIUM, INDIUM, AND/OR VANADIUM | CHEVRON U.S.A. INC. | 2004-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040124123-A1 | Hydrocarbon conversion using molecular sieve SSZ-63 | NSD3, HELZ, SPIN3 | HTR6 2326/4885PHGDH 3879/4885MGLL 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.